Breath Therapeutics, a Munich and Frankfurt, Germany-based provider of inhalation therapies for severe respiratory diseases, raised €43.5m in Series A funding.
The round was co-led by Gimv and Sofinnova Partners with participation from Gilde Healthcare. In conjunction with the funding, Graziano Seghezzi, partner at Sofinnova Partners, Dr. Karl Nägler, partner at Gimv, and Arthur Franken, partner at Gilde Healthcare, will join the board of directors.
The company intends to use the funds to conduct phase 3 trials in Europe and the US, respectively, submit for marketing approval, and prepare for commercialization.
Founded by Dr. Jens Stegemann (CEO), Anne Burger (CFO), Dr. Gerhard Boerner (CSO) and Dr. Oliver Denk (COO), Breath Therapeutics is advancing an inhalation therapy for treatment of Bronchiolitis Obliterans Syndrome (BOS), a lethal orphan respiratory disease, mainly affecting lung transplant patients.
Based on work by Starnberg, Germany-based PARI Pharma, the company which spun off Breath, and lung transplantation expert Aldo Iacono, MD, University of Maryland, USA, the company develops a proprietary drug/device combination. This involves a formulation of liposomal cyclosporine A for inhalation and an optimized high performance eFlow® technology nebulizer enabling remote adherence monitoring.